We work with pharma commercial leads in charge of pipeline therapies, innovators with new medical devices, and life science execs looking to expand their portfolio into new indications or defend against upcoming threats.
By addressing existing questions, testing hypotheses, and bringing fresh perspectives to discover unknown unknowns, we leave you better informed than before the project, with an outlined direction and recommended next steps to support your strategy and planning.
Depending on the project parameters and needs, we combine Competitive Intelligence (Primary and Secondary), Expert Interviews, Financial Analysis, Scientific Literature Reviews, Market Research (Qualitative and Quantitative), and Workshops. We collaborate to sequence the techniques thoughtfully and in a complementary way to deliver our projects.
Contact us on The SiVan Consulting Linkedin Company Page
Our clients’ needs are underpinned by several core questions: what are our customers (Payers, Physicians, and Patients) and competitors doing? How are they reacting to the macro factors (regulation, reimbursement, health, and lifestyle) in the space in which our therapy or medical device operates, and what should we do next to account for this?
Business development teams must stay on top of numerous therapy areas, with quicker developments, more competitors, and impactful regulatory, reimbursement or other macro factors.
We swiftly bring client teams up to speed with our established methodology, ensuring they are well-prepared to acquire the best therapies and avoid potentially costly mistakes.
Too often, companies get to a stage of development where negative external feedback is ignored because “too much” has been invested in a product, and the team has to make it work.
We inform innovative companies on the feasibility and desire for new therapies or medical devices, enabling them to correct them earlier in the development pathway.
Competing in life science markets is more challenging than ever, with governments, payers, patients, and physicians expecting more for less.
We bring a fresh perspective when engaging stakeholders to identify new exploitable opportunities and to better understand how to avoid or mitigate threats, enabling us to update your therapy or device strategy.
Understanding how your competitors operate is crucial. It helps you avoid their mistakes and identifies gaps in their thinking and strategy, enabling you to make informed decisions and take and maintain a lead in your space.
We help companies leap beyond the undifferentiated middle, assessing their output, processes, and structure against competitors to develop a new path forward.
Regardless of your function within Biopharma or Med tech, there is a need to understand external signals to support your drug or product, and develop smart strategies. If you’re seeking to understand competitors, patients, physicians or payors outside of your business, you’re an ideal client.
Simon delivered a great overview & perspective on available cutting edge modalities for IMIDs. The work delivered was shared with top management of I&I and received very well. It helped to define an action plan to stay abreast of the developments on these new modalities, to focus on the most promising approaches and to invest where appropriate.
Simon developed a comprehensive educational slide deck to foster key stakeholder engagement in new disease area. He was very responsive, with a high level of quality and well organized/ structured
Sivan Consulting were a reliable partner, with a transparent and open approach in our conversations and meetings. They provided a structured report of insights that were constructive, anonymous, objective, from key stakeholders following an Ad Board
It was excellent! We were aware it was the first time Simon was tackling such task, but his work was very thorough. Thanks to him, I think we have established a great framework for future Go-To-Market strategy work. He's a pleasure to work with.
Many life science consultancies overcomplicate using jargon and unnecessary complexity. We focus on simplicity, clarity and transparent evidence to deliver excellent results.
We've redesigned our operating model to put your needs at the center. By operating as a micro-boutique, we bring together specialized, experienced contributors to form fit-for-purpose teams without the heavy overhead of traditional consultancies.
This model provides benefits to our clients, Sivan Consulting, and the associates who work with us.
When we come together as a team, it will be no different from working with a larger consultancy and full-time staff. Individually and as a collective our reputation and ability to deliver high quality work are paramount.
Simon leans on experience from delivery of 100+ consulting projects to pharma, biotech, medtech and academia to support clients. He began his professional career in Competitive Intelligence consulting with big pharma for one of the major CI agencies, where he built strong attention to detail, and broad industry knowledge.
Since then has expanded broadened his experience and provided strategy consulting experience to projects across the product lifecycle for both drugs and medical devices, worked across a multitude of therapeutic areas and indications, and supported clients in R&D, BD, NPP, Medical affairs, market access, as well as brand/product leadership.
Today, he leads consulting projects for Sivan, supporting innovators in the life sciences approaching pivotal decisions to understand their external environment. From the earliest stage of engagement the focus is on understanding the client’s need, co-creating a project methodology that will address it, and collaborating throughout with the your team, and the associates supporting to deliver value.

Vera brings over nine years of experience helping top-10 global pharmaceutical companies protect and grow asset value through high-impact competitive intelligence and commercial strategy. She built her foundation at Cambridge Healthcare Research (CHR), a leading life sciences competitive intelligence consultancy, where she was among the earliest employees and played a key role in shaping differentiated CI approaches and best practices. During her tenure, she supported the firm’s growth from a small specialist team to a 100+ person organisation working with most major industry leaders.
Vera has led complex, global competitive monitoring and deep-dive programmes, delivering actionable insights across the full product life cycle, including for multiple blockbuster assets. Her work spans expert engagement, strategic workshops, and competitive benchmarking, with a strong track record of supporting critical brand, portfolio, and investment decisions. While experienced across therapeutic areas, she brings particular depth in autoimmune, infectious, and rare diseases.
As an independent consultant, Vera partners with consulting firms and emerging life science companies to design and deliver insight programmes that directly inform commercial strategy and drive decision-making impact. As a PhD-trained scientist, she combines deep technical credibility with strategic rigour and a pragmatic, outcomes-focused approach enabling clients to move from insight to action with confidence.

Sakis is an oncology drug development specialist with a keen interest in biomarker-driven development and in new targets. For the past 10 years he has worked almost exclusively in oncology, starting with a PhD in non-small cell lung cancer, followed by a 5-year tenure at GlobalData's Oncology and Hematology team. During that time, he developed an interest in patient-based forecasting aided by primary market research, refining and eventually transforming the team's approach. As part of numerous consulting projects, he supported oncology forecasting, CI, and market landscape deliverables.
Sakis started Celeritas Insights as an independent consultant in 2024, with a focus on supporting other consultancies or data vendors with oncology and forecasting expertise, as well as pharma and biotech companies with business intelligence needs spanning from forecasting to AI automation of CI processes. Sakis has developed an interest in the use of AI to transform pharma business intelligence, working with clients to automate manual processes, eventually creating and maintaining an independent database of pharma CI news and business catalysts.

Brandon is a senior supply chain professional with over 30 years’ experience leading complex supply chain operations across the pharmaceutical, medical device, aerospace and industrial sectors.
Brandon leads our Supply Chain practice where he helps supply chain leaders analyse, develop and operate world class supply chains. Brandon has extensive experience in supply chain strategy, S&OP and IBP deployment, logistics network optimisation, and ERP/SAP implementations, and has led multiple transformation and M&A integration/ due diligence programmes in highly regulated healthcare environments.
Most recently he served as Senior Director of Supply Operations for Accord Healthcare Europe, where he was responsible for procurement, logistics and supply across 30 European markets from a global supplier base.
